Company news
Skye Bioscience, Inc. news in 2022
Skye Bioscience, Inc.'s news releases, calls and decks from 2022, newest first.
Skye Bioscience Receives FDA Authorization of Investigational New Drug Application for SBI-100 OE
December 19, 2022
Skye Bioscience Doses First Cohort of Participants in Phase 1 Clinical Trial of SBI-100 Ophthalmic Emulsion
December 15, 2022
Skye Bioscience Appoints Chris Twitty, PhD, as Chief Scientific Officer
December 12, 2022
Skye Bioscience Submits Investigational New Drug Application for SBI-100 Ophthalmic Emulsion to FDA
November 16, 2022
Skye Bioscience Initiates First-in-Human Phase 1 Clinical Trial for SBI-100
November 15, 2022
Skye Bioscience Closes Acquisition of Emerald Health Therapeutics
November 9, 2022
Skye Bioscience Stockholders Vote in Favor of Arrangement Agreement with Emerald Health Therapeutics, Inc.
September 29, 2022
Skye Bioscience Completes Drug Production for Phase 1 Clinical Study
September 19, 2022
Skye Bioscience Files Definitive Proxy Statement and Announces Stockholder Meeting Date
August 31, 2022
Skye Bioscience Selects NextPharma as Phase 2 Contract Drug Manufacturer
July 20, 2022
Skye Bioscience Updates Phase 1 Timeline
July 19, 2022
Skye Bioscience Receives Australian Ethics Committee Approval to Start First-in-Human Phase 1 Study of SBI-100 Ophthalmic Emulsion
June 29, 2022
Skye Bioscience Expands Cannabinoid Pharmaceutical Innovation Program with Leading Cannabinoid Medicinal Chemistry Groups
June 6, 2022
Skye Bioscience Signs Arrangement Agreement with Emerald Health Therapeutics
May 11, 2022
Skye Bioscience Engages Clinical Trial Site for Phase 1 Study in Agreement with CMAX Clinical Research
April 27, 2022
Skye Bioscience Retains Novotech as CRO for Phase 1 Trial of Glaucoma Drug Candidate
March 2, 2022
Skye Bioscience Reports Positive Results for SBI-100 in GLP Toxicology Study
February 15, 2022
Skye Bioscience Reports Potential Neuroprotective Benefit of SBI-100 In Preclinical Glaucoma Model
January 31, 2022
Decks in 2022
- Investor Presentation (December 2022)
Investor deck · 26 slides · Dec 22, 2022
- Investor Presentation (December 2022)
Investor deck · 26 slides · Dec 2, 2022
- Investor Presentation (November 2022)
Investor deck · 28 slides · Nov 8, 2022
- Investor Presentation (September 2022)
Investor deck · 28 slides · September 2022
- Investor Presentation (August 2022)
Investor deck · 29 slides · August 2022
- Investor Presentation (July 2022)
Investor deck · 32 slides · July 2022
- Investor Presentation (June 2022)
Investor deck · 30 slides · June 2022
- Investor Presentation (May 2022)
Investor deck · 30 slides · May 26, 2022
- Investor Presentation (February 2022)
Investor deck · 24 slides · February 2022
- Investor Presentation (January 2022)
Investor deck · 24 slides · January 2022